These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24151207)

  • 1. Population-based meta-analysis of furosemide pharmacokinetics.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2014 Mar; 35(2):119-33. PubMed ID: 24151207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2013 Dec; 34(9):527-39. PubMed ID: 24123104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2013 Sep; 34(6):336-47. PubMed ID: 23794414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension.
    Shukla M; Ibrahim MMA; Jain M; Jaiswal S; Sharma A; Hanif K; Lal J
    Eur J Pharm Sci; 2017 Nov; 109():253-261. PubMed ID: 28821435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions.
    Kodati D; Yellu N
    Pharmacol Rep; 2017 Jun; 69(3):492-496. PubMed ID: 28340405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section.
    Gonçalves PVB; Moreira FL; Benzi JRL; Duarte G; Lanchote VL
    J Clin Pharmacol; 2020 Dec; 60(12):1655-1661. PubMed ID: 32562572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable furosemide absorption and poor predictability of response in elderly patients.
    Murray MD; Haag KM; Black PK; Hall SD; Brater DC
    Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure.
    Gottlieb SS; Khatta M; Wentworth D; Roffman D; Fisher ML; Kramer WG
    Am J Med; 1998 Jun; 104(6):533-8. PubMed ID: 9674715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects.
    Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M
    Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure.
    Chaturvedi PR; O'Donnell JP; Nicholas JM; Shoenthal DR; Waters DH; Gwilt PR
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):123-8. PubMed ID: 3557737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of reduced effects of loop diuretics in healthy volunteers and in patients with renal disease.
    Sjöström P
    Scand J Urol Nephrol Suppl; 1988; 111():1-66. PubMed ID: 3201162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs.
    Koh SK; Jeong JW; Choi SI; Kim RM; Koo TS; Cho KH; Seo KW
    BMC Vet Res; 2021 Sep; 17(1):295. PubMed ID: 34488750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus.
    Park JH; Lee WI; Yoon WH; Park YD; Lee JS; Lee MG
    Biopharm Drug Dispos; 1998 Sep; 19(6):357-64. PubMed ID: 9737816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis.
    Assy N; Kayal M; Mejirisky Y; Gorenberg M; Hussein O; Schlesinger S
    BMC Gastroenterol; 2006 Nov; 6():39. PubMed ID: 17134488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients.
    Tandra S; Chalasani N; Jones DR; Mattar S; Hall SD; Vuppalanchi R
    Ann Surg; 2013 Aug; 258(2):262-9. PubMed ID: 23222033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses.
    Knych HK; Vale A; Wilson WD; Kass PH; Arthur RM; Jones JH
    J Vet Pharmacol Ther; 2018 Apr; 41(2):224-229. PubMed ID: 29057472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.